Physician profile
Michael A Pappas
NPI 1437110442
$14,292.58
in general payments reported to CMS, 2019-2025
46 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $808 · 2021: $1,506 · 2022: $2,132 · 2023: $2,779 · 2024: $2,677 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,377 · Education: $56.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,376.70 |
| Education | $56.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,619.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,558.25 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,067.62 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,039.62 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $716.42 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $586.40 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $469.74 | 2022-2025 | Dupixent |
| Pfizer INC. | $450.85 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $407.05 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $301.51 | 2019-2025 | Rebyota, Clenpiq |
| Aimmune Therapeutics, INC. | $285.28 | 2023-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $282.90 | 2019-2025 | Sucraid |
| Celgene Corporation | $262.46 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $241.61 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $216.59 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $177.90 | 2022-2025 | Ibsrela |
| Daiichi Sankyo INC. | $153.89 | 2019-2023 | Injectafer |
| Neuraxis, INC. | $151.00 | 2025 | |
| Medtronic, INC. | $144.06 | 2022-2024 | Interstim |
| Braintree Laboratories, INC. | $118.31 | 2019-2023 | Sutab, Suflave |
| Lilly USA, LLC | $95.86 | 2024 | Omvoh |
| Ucb, INC. | $92.25 | 2019-2020 | |
| Romark Laboratories, Lc | $80.62 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.34 | 2023-2024 | Cyltezo |
| Madrigal Pharmaceuticals | $61.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $55.38 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $53.92 | 2019-2021 | |
| Shire North American Group INC | $44.87 | 2019 | |
| Merck Sharp & Dohme LLC | $43.29 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $40.72 | 2024-2025 | Iqirvo |
| Capsovision, INC. | $40.51 | 2024-2025 | Capsocam Plus |
| Enterra Medical, INC. | $38.45 | 2024 | |
| Ironwood Pharmaceuticals, INC | $37.09 | 2021-2024 | |
| Concordia Pharmaceuticals INC. | $36.20 | 2019 | |
| Organon LLC | $35.07 | 2023-2024 | Renflexis |
| Fresenius Kabi USA, LLC | $33.49 | 2023 | |
| Alexion Pharmaceuticals, INC. | $27.45 | 2019 | |
| Novo Nordisk INC | $21.71 | 2025 | Wegovy |
| Sandoz INC. | $21.60 | 2024 | Hyrimoz |
| Lucid Diagnostics INC. | $20.83 | 2024 | |
| Mylan Institutional INC. | $20.07 | 2023 | Hulio |
| Amgen INC. | $18.75 | 2023 | Avsola, Amjevita |
| Evoke Pharma, INC. | $17.62 | 2021 | |
| Mauna Kea Technologies, INC. | $14.29 | 2024 | |
| Endogastric Solutions, INC | $13.17 | 2023 | Esophyx |
| Vivus LLC | $12.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pappas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.